7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160
United States
510 474 0170
https://www.protagonist-inc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 112
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 1.03M | N/D | 1957 |
Mr. Mohammad Masjedizadeh Ph.D. | Executive VP & Chief Technical Officer | N/D | N/D | N/D |
Mr. Matthew M. Gosling | Executive VP & General Counsel | N/D | N/D | 1971 |
Ms. Carena Spivey | Head of HR & Senior VP of Human Resources | N/D | N/D | N/D |
Dr. Ashok Bhandari Ph.D. | Executive VP & Chief Drug Discovery and Preclinical Development Officer | N/D | N/D | 1964 |
Mr. Carter J. King | Executive Vice President of Business Development | N/D | N/D | 1971 |
Ms. Abha Bommireddi | Executive Vice President of Portfolio & Program Management | N/D | N/D | N/D |
Dr. Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer | N/D | N/D | 1959 |
Craig Ostroff Pharm.D., R.Ph. | Interim Head of Regulatory Affairs & Advisor | N/D | N/D | N/D |
Dr. Samuel R. Saks M.D. | Clinical Development Advisor | N/D | N/D | 1955 |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
La calificación ISS Governance QuickScore de Protagonist Therapeutics, Inc. a partir del 29 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 6; Derechos del accionista: 7; Compensación: 7.